Hosted on MSN1mon
Kezar struck again with second FDA holdKezar Life Sciences has been handed a second clinical hold by the US Food and Drug Administration (FDA) in as many months. The FDA told the San-Francisco based biotech to halt the PALIZADE study ...
US-based biopharmaceutical company Kezar Life Sciences has suspended subject enrolment and patient dosing in the Phase II PALIZADE trial of zetomipzomib for active lupus nephritis. The decision to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback